匯川技術(300124.SZ):精密機械是公司重要的產品板塊
格隆匯8月23日丨有投資者向匯川技術(300124.SZ)提問:精密傳動方面,看到今年上半年公司收購了韓國SBC公司,請問公司在精密機械方面的規劃如何?
匯川技術回覆:精密機械產品是中國製造業的短板。在設備自動化中,精密機械市場基本上被日本、台灣等品牌佔據,中國品牌較少。公司2016年通過併購的方式補充了絲槓產品,這兩年成長較好,較多應用在全電動注塑機和SCARA機器人上。今年上半年收購了韓國SBC公司,補充了精密直線導軌產品,該產品廣泛應用於機牀、3C等行業。
精密機械,是公司重要的產品板塊,是公司落地“光、機、電、氣、液”綜合解決方案的重要一環。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.